The Repurposing of Prednisolone: Inhibition on the Formation of Pancreatic Cancer Associated Fibroblasts (CAFs) Through Ets1-HMGXB3 Axis
ISEF · 2024 Biomedical and Health Sciences
Overview
Pancreatic cancer is one of the deadliest diseases in the world. Cancer-associated fibroblasts (CAFs) are an important component of the tumor microenvironment (TME) and important immune-negative regulatory cells, playing a key role in tumor cell proliferation and metastasis. However, previous pancreatic cancer therapies such as surgery, radiation therapy, or chemotherapy are expensive and have severe side effects. The aim of this study was to screen for risk genes in pancreatic CAFs, find upstream targets, screen for drugs, and ameliorate the structure to target pancreatic CAFs. Based on Normal fibroblasts and serum-induced CAFs cell model, this study starts with performing RNA sequencing, proteomics and RT-qPCR analyses, which identified HMGXB3 as the crucial genetic signature in pancreatic CAFs. Further bioinformatic analysis unveiled Ets1 as a prime candidate transcription factor for HMGXB3. Targeting the upstream transcription factor Ets1, the drugs were screened by automated docking software, molecular dynamics software, and CCK8 experiments. It was found that prednisolone, a drug targeting CAFs, had a significant inhibitory effect on CAFs, whereas it did not have a significant inhibitory effect on normal fibroblasts. The targeting effect of prednisolone on Ets1-HMGXB3 axis was further verified by Western blot and RT-qPCR analysis. Study on the concentration gradient of prednisolone revealed 60µM as the most effective concentration. Finally, Molecular Operating Environment (MOE) software simulated possible structural improvements of the drugs. Overall, this study illuminates that prednisolone is an effective potential candidate for the treatment of pancreatic cancer by targeting the Ets1-HMGXB3 axis of pancreatic CAFs.
Competition history
- ISEF 2024
Resources
Related projects
ISEF · 2025
Decoding PDAC: A scRNA-seq Omics Analysis to Unveil and Inhibit Key Protein Using a Novel in-silico, Structure-Based Drug Design Pipeline
ISEF · 2022
Altering Metabolic Pathways To Override Drug Resistance in Cancer
ISEF · 2020
A Potential Pancreatic Cancer Treatment in Pre-mRNA Splicing Inhibition: An Innovative Approach by Identifying Vulnerabilities in Pancreatic Cancer Cells Using Biflavonoid Isoginkgetin and Pladienolide B
ISEF · 2026
Next Generation Cancer Therapeutics: Peptide Binder Impairing Oncogenic KRAS Signalling by Inhibition of KRAS–PDEd Interaction
Closest projects by meaning, across every fair and year in the corpus.
Source: Regeneron International Science and Engineering Fair